These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 22496676

  • 1. Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value.
    Nadin C.
    Core Evid; 2005; 1(1):43-63. PubMed ID: 22496676
    [Abstract] [Full Text] [Related]

  • 2. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, Strippoli GF.
    Cochrane Database Syst Rev; 2018 Aug 22; 8(8):CD006023. PubMed ID: 30132304
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA, Shepler BM.
    Pharmacotherapy; 2010 Jul 22; 30(7):741-8. PubMed ID: 20575637
    [Abstract] [Full Text] [Related]

  • 4. Update and critical appraisal of sevelamer in the management of chronic renal failure.
    Grinfeld J, Inaba A, Hutchison AJ.
    Open Access J Urol; 2010 Sep 02; 2():161-70. PubMed ID: 24198624
    [Abstract] [Full Text] [Related]

  • 5. Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.
    Nolan CR, Qunibi WY.
    Curr Opin Nephrol Hypertens; 2003 Jul 02; 12(4):373-9. PubMed ID: 12815333
    [Abstract] [Full Text] [Related]

  • 6. Slowing the progression of vascular calcification in hemodialysis.
    Chertow GM.
    J Am Soc Nephrol; 2003 Sep 02; 14(9 Suppl 4):S310-4. PubMed ID: 12939387
    [Abstract] [Full Text] [Related]

  • 7. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF.
    Am J Kidney Dis; 2009 Oct 02; 54(4):619-37. PubMed ID: 19692157
    [Abstract] [Full Text] [Related]

  • 8. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients.
    Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E.
    Am J Kidney Dis; 1999 Apr 02; 33(4):694-701. PubMed ID: 10196011
    [Abstract] [Full Text] [Related]

  • 9. Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients.
    Ossareh S.
    Int J Nephrol Renovasc Dis; 2014 Apr 02; 7():161-8. PubMed ID: 24855385
    [Abstract] [Full Text] [Related]

  • 10. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.
    Gallieni M, Cozzolino M, Carpani P, Zoni U, Brancaccio D.
    J Nephrol; 2001 Apr 02; 14(3):176-83. PubMed ID: 11439741
    [Abstract] [Full Text] [Related]

  • 11. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis.
    Nolan CR, Qunibi WY.
    Kidney Int Suppl; 2005 Jun 02; (95):S13-20. PubMed ID: 15882308
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ.
    Saudi Med J; 2004 Jun 02; 25(6):785-91. PubMed ID: 15195212
    [Abstract] [Full Text] [Related]

  • 13. Hyperphosphataemia: treatment options.
    Malberti F.
    Drugs; 2013 May 02; 73(7):673-88. PubMed ID: 23625273
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
    Brunner-Ziegler S, Fröschl B, Hiebinger C, Zsifkovits J.
    Ann Nutr Metab; 2011 Oct 02; 58(4):315-9. PubMed ID: 21986491
    [Abstract] [Full Text] [Related]

  • 15. Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification.
    Braun J, Asmus HG, Holzer H, Brunkhorst R, Krause R, Schulz W, Neumayer HH, Raggi P, Bommer J.
    Clin Nephrol; 2004 Aug 02; 62(2):104-15. PubMed ID: 15356967
    [Abstract] [Full Text] [Related]

  • 16. [Pharmacological and clinical trial data on a novel phosphate-binding polymer (sevelamer hydrochloride), a medicine for hyperphosphatemia in hemodialysis patients].
    Nagano N, Fukushima N.
    Nihon Yakurigaku Zasshi; 2003 Nov 02; 122(5):443-53. PubMed ID: 14569164
    [Abstract] [Full Text] [Related]

  • 17. Phosphate binders: Sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure.
    Spaia S.
    Hippokratia; 2011 Jan 02; 15(Suppl 1):22-6. PubMed ID: 21897754
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness and cost-efficiency of phosphate binders in hemodialysis.
    Fröschl B, Brunner-Ziegler S, Hiebinger C, Wimmer A, Zsifkovits J.
    GMS Health Technol Assess; 2009 Jun 05; 5():Doc08. PubMed ID: 21289895
    [Abstract] [Full Text] [Related]

  • 19. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, Umanath K, Abraham JD, Arfeen SS, Bowline IG, Chernin G, Fadem SZ, Goral S, Koury M, Sinsakul MV, Weiner DE, Collaborative Study Group.
    Am J Kidney Dis; 2015 Sep 05; 66(3):479-88. PubMed ID: 25958079
    [Abstract] [Full Text] [Related]

  • 20. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
    Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, Braun J, Chertow GM.
    J Bone Miner Res; 2005 May 05; 20(5):764-72. PubMed ID: 15824849
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.